Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976154 | 0.81 | — | — | |
| SCHEMBL11108863 | 0.78 | CYP2D6 (0.43) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL5756982 | 0.76 | CYP2D6 (0.42) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL8143628 | 0.74 | CA2 (0.41) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL3164862 | 0.74 | CA2 (0.55) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL12531860 | 0.74 | CA2 (0.55) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL18654249 | 0.74 | CA2 (0.55) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL18654350 | 0.74 | CA2 (0.55) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL18105805 | 0.73 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL15040789 | 0.73 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956039-B2 | Use of amygdalin analogues for the treatment of psoriasis | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2011-06-07 | — | — | US | disclosed |
| US-20080125378-A1 | Use of Amygdalin Analogues for the Treatment of Psoriasis | UNIVERSITAT POLITECNICA DE CATALUNYA (ES) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125378-A1 | Use of Amygdalin Analogues for the Treatment of Psoriasis | C3AR1, CCR7, C5AR1 | CYP2D6 571/4885THRB 3130/4885HSD17B10 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.